Up to the present times, the endocannabinoid systems are known to have broad effects on a variety of tissues. It has also indicated to profoundly influence cardiovascular and immune systems as well as controlling progenitor cell proliferations (1-3). Mike Membrino, maintains that cannabinoids receptors (CB1 & CB2) have arose as a dominant player in the multifaceted web of neuromodulators, establishing a new intercellular communiqué network mostly convoluted in the controller of neurotransmitter announcement.
Additionally, Michael Membrino, President of Neuro-Endoceuticals asserts that there are two major interactive systems within the ECS, including cannabinoids receptors that are found on the cell surfaces and endocannabinoids that fit the receptors that trigger numerous metabolic processes. CB1 receptors are present in the very high levels in several brain regions and lower quantities in additional extensive fashion. These receptors arbitrate numerous of the psychoactive belongings of cannabinoids.
On the other hand, CB2 has a more restricted distribution, being located and found in some immune cells and a few neurons. This receptor is believed to serve a significant role in immune function and inflammation. Both CB1 and CB2 couple central to inhibitory G-protein and are subjected to the same pharmacological influence as other G-protein coupled receptors. The primary explanation is that the differential binding of CB1 and CB2 receptors either can lead to various physiological effects mediated through neurotransmitters.